Metronidazole
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NUVESSA | — | 2018-08-03 | fda.gov ↗ |
| Label expansion | US (FDA) | METROGEL-VAGINAL | — | 1997-05-16 | fda.gov ↗ |
| Label expansion | US (FDA) | FLAGYL I.V. RTU IN PLASTIC CONTAINER | — | 1988-02-17 | fda.gov ↗ |
| Label expansion | US (FDA) | FLAGYL | — | 1988-02-10 | fda.gov ↗ |
| Approved | US (FDA) | FLAGYL | — | 1963-07-18 | fda.gov ↗ |
Trials 317 · started per year
Also used as a comparator or background therapy in 293 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT06640439 Background | Oct 2024 → Feb 2025 overdue | impacted teeth, multiple | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05829109 Background | Sep 2024 → Dec 2026 expected | pouchitis | Maia Kayal | Recruiting | No outcome recorded |
| Phase 0 | NCT06135974 Background | Feb → Dec 2024 | bacterial vaginosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04968951 Comparator | Nov 2021 → Aug 2022 | ulcerative colitis | Ari M Grinspan | Terminated | No outcome recorded |
| Phase 0 | NCT03042091 Background | Sep 2016 → Oct 2020 | colorectal neoplasm, diverticulitis, inflammatory bowel disease | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 0 | NCT02197182 Comparator | Jun 2014 → Mar 2015 | bacterial vaginosis | CDA Research Group, Inc. | Terminated | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 0 | NCT01731236 Comparator | Feb 2011 → Dec 2027 expected | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT03954990 Comparator | Oct 2019 → Sep 2022 | bacterial vaginosis | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 1 | NCT04066257 Comparator | Jan → Feb 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03337126 Comparator | Nov → Dec 2017 | — | Appili Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02947763 Comparator | Nov 2016 → Jan 2018 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT01534247 Comparator | Feb → Jul 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01020877 Comparator | Nov 2001 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03727620 Comparator | Jan → Jun 2014 | periodontitis, aggressive | Mohammed V Souissi University | Completed | No outcome recorded |
| Phase 1/2 | NCT01762670 Comparator | Feb → Dec 2013 | bacterial vaginosis | CDA Research Group, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00817245 Comparator | Mar → Oct 2008 | central serous chorioretinopathy | Tabriz University | Completed | No outcome recorded |
| Phase 230 trials | ||||||
| Phase 2 | NCT07566754 Comparator | Sep 2026 → May 2027 expected | bacterial vaginosis | Douglas Kwon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07492134 Comparator | Jul 2026 → Apr 2028 expected | diverticulitis | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07144657 Background | Sep 2025 → Dec 2029 expected | gastric mucosa-associated lymphoid tissue lymphoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05943223 Comparator | Sep 2024 → Jul 2025 | appendicitis | McMaster Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04273997 Comparator | Oct 2021 → Feb 2022 | pilonidal sinus | S.L.A. Pharma AG | Unknown | No outcome recorded |
| Phase 2 | NCT07418996 Comparator | May 2021 → Jul 2022 | bacterial vaginosis | Guangdong Longchuangji Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04729322 Background | Feb 2021 → Dec 2027 expected | colorectal adenocarcinoma, small intestine adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04264676 Comparator | Mar 2020 → Mar 2023 | colorectal cancer | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT04238091 Comparator | Dec 2019 → Mar 2022 | alopecia areata, alopecia totalis, alopecia universalis | Lindsey Bordone | Withdrawn | No outcome recorded |
| Phase 2 | NCT03986996 Comparator | Jul 2019 → May 2022 | ulcerative colitis | Wolfson Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03656484 Comparator | Jan → Dec 2019 | chronic periodontitis | Concordia Dent Srl | Completed | No outcome recorded |
| Phase 2 | NCT03327844 Comparator | Mar 2017 → Jul 2021 | — | National University Health System, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT02766023 Background | Jun 2016 → Feb 2019 | bacterial vaginosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02655419 Background | May 2016 → Oct 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02606032 Comparator | May 2016 → Jan 2021 | ulcerative colitis | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02789865 Comparator | May 2016 → Apr 2018 | appendicitis | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT02376972 Comparator | Apr 2015 → Feb 2016 | bacterial vaginosis | Alfasigma S.p.A. | Terminated | No outcome recorded |
| Phase 2 | NCT02334163 Comparator | Dec 2014 → Feb 2015 | hepatic encephalopathy | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02857582 Background | Oct 2014 → Oct 2018 | Clostridium difficile colitis | Per Hellström | Completed | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT02148601 Comparator | Jul 2013 → Nov 2014 | Clostridium difficile colitis | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 2 | NCT01361048 Comparator | Dec 2011 → Aug 2012 | Trichomonas vaginitis urogenital infection | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01449591 Comparator | Sep 2011 → Feb 2012 | rosacea | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01160640 Comparator | Nov 2010 → Aug 2015 | pelvic inflammatory disease | Harold Wiesenfeld | Completed | No outcome recorded |
| Phase 2 | NCT01147640 Background | Jun 2010 → Feb 2011 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01055106 Comparator | Jan → Apr 2010 | bacterial vaginosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01938183 Comparator | Nov 2006 → Mar 2010 | chronic periodontitis | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 2 | NCT00066066 Comparator | Jul 2003 → Jul 2009 | periodontitis | The Forsyth Institute | Completed | No outcome recorded |
| Phase 2 | NCT00066001 Comparator | Dec 2002 → Dec 2007 | periodontitis | The Forsyth Institute | Completed | No outcome recorded |
| Phase 2 | NCT00153517 Comparator | Oct 1999 → Sep 2004 | bacterial vaginosis, chorioamnionitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/320 trials | ||||||
| Phase 2/3 | NCT06821763 Comparator | May → Oct 2025 overdue | periodontitis, pulpitis | Komal Ashraf Khan | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06006663 Comparator | Aug → Oct 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03226626 Background | Dec 2021 → Jan 2022 | infectious disease with sepsis, thrombotic disease | HK Surgical, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04827537 Comparator | Jan 2021 → Dec 2026 expected | giardiasis | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05222737 Comparator | Jan → Sep 2021 | periodontitis | Alexandria University | Completed | No outcome recorded |
| Phase 2/3 | NCT04276298 Comparator | Sep 2020 → Feb 2022 | hemorrhoid | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 2/3 | NCT04009772 Comparator | Jul 2019 → Feb 2020 | skin infection | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04030741 Comparator | Sep 2018 → Dec 2019 | appendicitis | King Edward Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT02686645 Background | Dec 2016 → Dec 2021 | Clostridium difficile colitis | Queen Elizabeth II Health Sciences Centre | Unknown | No outcome recorded |
| Phase 2/3 | NCT02466698 Background | Aug 2016 → Aug 2019 | Clostridium difficile colitis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 2/3 | NCT02503904 Comparator | Oct 2015 → Jun 2019 | venous thromboembolism | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02969928 Comparator | Mar 2015 → Dec 2016 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT03132714 Comparator | Mar 2015 → Oct 2016 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT02301000 Comparator | Feb 2015 → Nov 2017 | Clostridium difficile colitis | Oslo University Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT02365389 Comparator | May → Oct 2014 | vaginitis | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT00799214 Comparator | Apr 2014 → Nov 2015 | bacterial vaginosis | University of British Columbia | Completed | No outcome recorded |
| Phase 2/3 | NCT01994993 Comparator | Dec 2013 → Jan 2017 | — | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 2/3 | NCT01089348 Comparator | Jul → Oct 2010 | bacterial vaginosis | Avva Rus, JSC | Unknown | No outcome recorded |
| Phase 2/3 | NCT01937650 Comparator | Jun 2009 → Apr 2010 | cervical carcinoma | Makerere University | Completed | No outcome recorded |
| Phase 2/3 | NCT00536848 Background | Oct 2007 → Aug 2008 | HIV infectious disease, bacterial vaginosis, diarrheal disease | National Institute for Medical Research, Tanzania | Unknown | No outcome recorded |
| Phase 348 trials | ||||||
| Phase 3 | NCT06847126 Comparator | Feb 2025 → Jun 2026 overdue | liver abscess (disease) | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT06760065 Comparator | Jan 2025 → Dec 2027 expected | Helicobacter pylori infectious disease | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06443502 Background | Nov 2024 → Dec 2029 expected | pouchitis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06633718 Comparator | Oct 2024 → May 2027 expected | infectious peritonitis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07487142 Comparator | Jun 2024 → Dec 2025 | Helicobacter pylori infectious disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT05681312 Comparator | May → Sep 2024 | — | University of Baghdad | Unknown | No outcome recorded |
| Phase 3 | NCT06107569 Comparator | May 2024 → Dec 2025 | Clostridium difficile colitis | Hospital Universitario Evangelico de Curitiba | Unknown | No outcome recorded |
| Phase 3 | NCT07304882 Background | Nov 2023 → Jan 2025 | impacted teeth, multiple | University of Science and Technology, Yemen | Completed | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04549311 Comparator | Nov 2021 → Jan 2023 | anal fistula | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT04415983 Comparator | Jun 2020 → Oct 2030 expected | Helicobacter pylori infectious disease | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT04189744 Comparator | Dec 2019 → Oct 2022 | Trichomonas vaginitis urogenital infection, bacterial vaginosis, malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03969758 Comparator | Jul 2019 → May 2020 | liver abscess (disease) | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT03688295 Comparator | Feb 2019 → Sep 2025 overdue | appendicitis | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT03358576 Comparator | Sep 2018 → Oct 2019 | intestinal infectious disease | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03779074 Comparator | Sep 2018 → Dec 2021 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 3 | NCT04209777 Comparator | Jul 2018 → Apr 2019 | chronic periodontitis | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03329092 Background | Apr 2018 → Feb 2023 | nosocomial infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03182907 Background | Mar 2018 → May 2022 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03091777 Comparator | Mar → Nov 2017 | bacterial vaginosis | Balmoral Medical company | Completed | No outcome recorded |
| Phase 3 | NCT03142607 Comparator | Feb 2017 → Jan 2018 | gingivitis | Aga Khan University | Unknown | No outcome recorded |
| Phase 3 | NCT02827942 Comparator | Jul 2016 → Dec 2018 | bacterial gastritis | Hamamatsu University | Completed | No outcome recorded |
| Phase 3 | NCT02186145 Background | Jan 2016 → Jan 2017 | bacterial vaginosis | Marjan Industria e Comercio ltda | Unknown | No outcome recorded |
| Phase 3 | NCT02308033 Comparator | Jun 2015 → Jun 2017 | infective vaginitis | Curatek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02308007 Comparator | Jun 2015 → Jun 2018 | infective vaginitis | Curatek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02276482 Background | Mar 2015 → Sep 2018 | skin disease caused by bacterial infection, skin infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02393937 Comparator | Feb → Jul 2015 | rosacea | bioRASI, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02422706 Comparator | Jan 2015 → Dec 2018 | gastritis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02237950 Background | Oct 2014 → Dec 2016 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02236156 Background | Oct 2014 → Jul 2016 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02112214 Comparator | Jun 2014 → Dec 2029 expected | Helicobacter pylori infectious disease, gastric cancer | National Cancer Center, Korea | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03374176 Comparator | Mar 2014 → Jul 2016 | chronic periodontitis, type 2 diabetes mellitus | Centro Universitario de Tonalá | Completed | No outcome recorded |
| Phase 3 | NCT02328144 Comparator | Jul 2013 → Aug 2014 | hemorrhoid | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 3 | NCT01644643 Background | Jan 2013 → Sep 2014 | urinary tract infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01564823 Comparator | Jun 2012 → Jan 2015 | Crohn disease | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Completed | No outcome recorded |
| Phase 3 | NCT01493947 Comparator | Apr 2012 → Dec 2013 | rosacea | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01513239 Background | Feb 2012 → May 2015 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01481844 Comparator | Nov 2011 → Dec 2014 | — | Soroka University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01241552 Background | Oct 2011 → Dec 2014 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01658852 Comparator | May 2011 → May 2014 | postgastrectomy syndrome | The Catholic University of Korea | Withdrawn | No outcome recorded |
| Phase 3 | NCT01602874 Comparator | Jan 2011 → May 2014 | bacterial pneumonia | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00914888 Comparator | Jan 2011 → May 2014 | bacterial pneumonia | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT01254344 Comparator | Dec 2010 → Dec 2011 | infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00741845 Comparator | Jun 2008 → Jun 2009 | bacterial vaginosis | Embil Pharmaceutical Co. Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT00508690 Comparator | Sep 2007 → Dec 2011 | colorectal neoplasm | Japan Multinational Trial Organization | Completed | No outcome recorded |
| Phase 3 | NCT00453349 Comparator | Jan 2007 → May 2008 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00769171 Comparator | Oct 2005 → Dec 2006 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00683865 Comparator | Apr 2003 → Oct 2004 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 4112 trials | ||||||
| Phase 4 | NCT07625267 Comparator | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07180615 Comparator | Jun 2026 → Jan 2028 expected | — | University of Lucerne | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Show all 112 trials opens the full record — a long page | ||||||
| Phase not applicable66 trials | ||||||
| — | NCT07043855 Comparator | May 2026 → Oct 2028 expected | infectious disease | Asan Medical Center | Enrolling by invitation | No outcome recorded |
| — | NCT05434104 Comparator | Apr 2026 → Dec 2027 expected | bacterial vaginosis, vulvovaginal candidiasis | Guy's and St Thomas' NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT05383521 Background | Dec 2025 | Trichomonas vaginitis urogenital infection | Shangrong Fan | Unknown | No outcome recorded |
| — | NCT07358130 Comparator | Oct 2025 → Nov 2027 expected | Helicobacter pylori infectious disease | Kaohsiung Medical University | Recruiting | No outcome recorded |
| — | NCT06926322 Comparator | Oct 2025 → Aug 2027 expected | dental pulp necrosis, neuropathy, painful, root resorption | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT07165444 Comparator | Sep 2025 → Feb 2026 overdue | Helicobacter pylori infectious disease, proton-pump inhibitor-responsive esophageal eosinophilia | Tanta University | Recruiting | No outcome recorded |
| — | NCT06517264 Comparator | Nov 2024 → Apr 2026 overdue | diverticulitis of colon | Monica Mengual Ballester | Enrolling by invitation | No outcome recorded |
| — | NCT06510452 Comparator | Oct 2024 → Dec 2025 overdue | — | General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting | No outcome recorded |
| — | NCT07260006 Background | Oct 2024 → May 2026 overdue | Helicobacter pylori infectious disease, peptic ulcer disease | Can Tho University of Medicine and Pharmacy | Recruiting | No outcome recorded |
| — | NCT07247851 Comparator | Jan → Jun 2024 | bacterial vaginosis | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| — | NCT06583863 Comparator | Sep 2023 → Apr 2024 | ulcerative colitis | Benha University | Completed | No outcome recorded |
| — | NCT06004401 Comparator | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT04723472 Background | Aug 2023 → Dec 2025 | Helicobacter pylori infectious disease | Shanghai East Hospital | Suspended | No outcome recorded |
| — | NCT05677945 Background | Mar 2023 → Mar 2024 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT06174909 Comparator | Nov 2022 → Aug 2023 | — | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT05275894 Background | Oct 2022 → Mar 2024 | periodontitis | Universidad Complutense de Madrid | Unknown | No outcome recorded |
| — | NCT05323396 Comparator | May 2022 → Aug 2023 | coinfection | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT03643198 Comparator | Mar 2022 | abscess, anal fistula | Germans Trias i Pujol Hospital | Unknown | No outcome recorded |
| — | NCT03939273 Comparator | Mar 2022 → Mar 2023 | autoinflammatory syndrome, coronary artery disorder | Radboud University Medical Center | Unknown | No outcome recorded |
| — | NCT04998513 Comparator | Jan 2022 | peritonsillar abscess | Nova Scotia Health Authority | Withdrawn | No outcome recorded |
| — | NCT05385887 Comparator | Dec 2021 → Dec 2024 | abscess, anal fistula | dr. IJM Han-Geurts | Unknown | No outcome recorded |
| — | NCT04879992 Comparator | May 2021 → Oct 2022 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT04803422 Comparator | Apr 2021 → May 2024 | appendicitis | Zealand University Hospital | Completed | No outcome recorded |
| — | NCT04674774 Background | Mar 2021 → Feb 2022 | Helicobacter pylori infectious disease | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT06382493 Background | Feb 2021 → Dec 2026 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT04359966 Comparator | May 2020 → May 2023 | Helicobacter pylori infectious disease | Slovenian Society for Gastroenterology and Hepatology | Unknown | No outcome recorded |
| — | NCT05850117 Comparator | Feb 2020 → Dec 2024 | — | Kaohsiung Medical University | Unknown | No outcome recorded |
| — | NCT05038605 Comparator | Jan 2020 → Jan 2021 | anal fistula, hemorrhoid | Mansoura University | Completed | No outcome recorded |
| — | NCT03844776 Comparator | Oct 2019 → Dec 2020 | infectious disease | Taibah University | Unknown | No outcome recorded |
| — | NCT05445362 Comparator | Feb 2019 → Aug 2020 | — | Reham Hassan | Completed | No outcome recorded |
| — | NCT04621487 Comparator | Jan 2019 → Jan 2020 | Helicobacter pylori infectious disease | University of Split, School of Medicine | Completed | No outcome recorded |
| — | NCT05152004 Comparator | Sep 2018 → Nov 2021 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT03412071 Comparator | Dec 2017 → Dec 2019 | — | University of Toronto | Unknown | No outcome recorded |
| — | NCT03326661 Comparator | Nov 2017 → Nov 2019 | peritonsillar abscess | Odense University Hospital | Unknown | No outcome recorded |
| — | NCT03499184 Comparator | Nov 2017 → Sep 2018 | chronic periodontitis | Ziauddin Hospital | Completed | No outcome recorded |
| — | NCT03257423 Comparator | Apr 2017 → Dec 2022 | appendicitis | Turku University Hospital | Unknown | No outcome recorded |
| — | NCT03236961 Comparator | Apr 2017 → Nov 2018 overdue | appendicitis | Turku University Hospital | Active not recruiting | No outcome recorded |
| — | NCT03829150 Background | Mar 2017 → Apr 2019 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT03079388 Background | Feb 2017 → Sep 2019 | nutritional disorder, pregnancy disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT03321773 Comparator | Jan 2017 → Dec 2020 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| — | NCT03763110 Comparator | Oct 2016 → Dec 2018 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT03383003 Comparator | Mar 2016 → May 2018 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT03043066 Comparator | Mar → Jul 2016 | chronic periodontitis | Meenakshi Ammal Dental College and Hospital | Completed | No outcome recorded |
| — | NCT02759029 Comparator | Mar 2016 → Feb 2018 | Helicobacter pylori infectious disease | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT02756403 Comparator | Mar 2016 → Jul 2017 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| — | NCT04061447 Comparator | Feb 2016 → May 2019 | Helicobacter pylori infectious disease | Kaohsiung Medical University | Completed | No outcome recorded |
| — | NCT02954393 Comparator | May 2015 → Dec 2019 | chronic periodontitis | Belén Retamal-Valdes | Unknown | No outcome recorded |
| — | NCT02547038 Comparator | Feb 2015 → Oct 2018 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02744638 Background | Feb 2015 → Aug 2016 | bacterial vaginosis | Clinical Research Center Kiel GmbH | Completed | No outcome recorded |
| — | NCT02359331 Comparator | Aug 2014 → Dec 2022 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Terminated | No outcome recorded |
| — | NCT02373280 Comparator | Aug 2014 → Apr 2027 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT02159976 Comparator | Jul 2014 → May 2015 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT02314013 Comparator | Apr 2014 → Nov 2016 | diverticulitis of colon | Dongtan Sacred Heart Hospital | Unknown | No outcome recorded |
| — | NCT01643785 Background | Jun 2012 → Jun 2013 | Helicobacter pylori infectious disease | Chuncheon Sacred Heart Hospital | Terminated | No outcome recorded |
| — | NCT01723059 Comparator | Feb 2012 → Jan 2013 | Helicobacter pylori infectious disease | Dallas VA Medical Center | Unknown | No outcome recorded |
| — | NCT01472978 Comparator | Dec 2011 → Dec 2014 | Clostridium difficile colitis | State University of New York at Buffalo | Withdrawn | No outcome recorded |
| — | NCT01322971 Comparator | Feb 2011 → Jun 2012 | bacterial vaginosis, infertility disorder, pregnancy disorder with abortive outcome | Stanford University | Terminated | No outcome recorded |
| — | NCT03507556 Background | Jun 2010 → Nov 2021 overdue | — | Jordan University of Science and Technology | Active not recruiting | No outcome recorded |
| — | NCT01255670 Comparator | Feb 2010 → Apr 2011 | peritonsillar abscess | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT01306786 Comparator | Nov 2008 → Oct 2010 | Helicobacter pylori infectious disease | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00545181 Comparator | Sep 2007 → Jul 2009 | bacterial vaginosis | Indiana University | Completed | No outcome recorded |
| — | NCT00462020 Comparator | Mar 2007 → Nov 2008 | appendicitis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00353743 Comparator | May 2006 → Nov 2007 | — | Hospital de Clinicas de Porto Alegre | Terminated | No outcome recorded |
| — | NCT00720291 Comparator | Feb 2006 → Nov 2010 | bacterial vaginosis | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 618 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Métronidazole | “in patients who failed a first line treatment , or to treatment guided by the molecular test: PPI , amoxicillin 1g, clarithromycin 500 mg X 2 /day for 7 days in case of...” NCT01168063 ↗590“14-day bismuth quadruple therapy (pantoprazole, bismuth subcitrate, tetracycline, and metronidazole for 14 days) or 14-day hybrid therapy (a 7-day dual therapy with...” PMID 28807915 ↗ Oct 2017 “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗ “The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams,...” NCT04998513 ↗ “A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e.,...” NCT06687473 ↗ “Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or...” PMID 39434634 ↗ Sep 2024 “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “Group 1: (110) participants received reverse hybrid regimen in the form of clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500 mg tid for...” NCT04039412 ↗ “In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral...” NCT01111253 ↗ “esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5...” NCT01547559 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 “A gel (experimental: metronidazole VS control: carbopol) is introduced in the recently cleaned periodontal pocket. The allocation of either experimental or control gel was...” NCT06836401 ↗ “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin,...” NCT02168816 ↗ “sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe...” NCT01418300 ↗ “Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of...” NCT00712413 ↗ “patients will receive concomitant therapy comprising of pantoprazole (40 mg twice daily), amoxicillin (1 gm twice a day), clarithromycin (500 mg twice a day) and metronidazole...” NCT06050824 ↗ “A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all...” NCT07146594 ↗ “ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin...” NCT03182907 ↗ “10-day ST (30 mg lansoprazole/1 g amoxicillin, each administered twice daily for 5 days followed by 30 mg lansoprazole/500 mg clarithromycin/400 mg metronidazole, each...” PMID 29804294 ↗ Jun 2018 “Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month,...” NCT04669717 ↗ “Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole...” NCT00885417 ↗ “Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of...” NCT01241110 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg...” NCT02916134 ↗ “Patients randomized to antibiotic therapy received intravenous ertapenem (1 g/d) for 3 days followed by 7 days of oral levofloxacin (500 mg once daily) and metronidazole (500...” PMID 26080338 ↗ Jun 2015 “(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days :...” NCT02108184 ↗ “They will be randomized into one of two arms; metronidazole (MTZ) 2 g single dose (CDC recommended treatment regimen) or MTZ 500 mg twice daily x 7-day dose (CDC alternative...” NCT01832480 ↗ “per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a...” NCT04447625 ↗ “per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a...” NCT05205993 ↗ “SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV...” NCT01513239 ↗ “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗ “The intervention group will be treated with Esomeprazole 40 mg every 8 hours, Amoxicillin 1 gr every 8 hours, Metronidazole 500 mg every 8 hours, Bismuth subsalicylate 369 mg...” NCT05664685 ↗ “One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night,...” NCT01867164 ↗ “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic...” NCT03598842 ↗ “Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours.” NCT04030741 ↗ “oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days” NCT04674774 ↗ “tumescent formulation of cefazolin (1gm) and metronidazole (500mg/100ml) in a dilute solution of lidocaine (1gm), epinephrine (1mg) in 100ml and sodium bicarbonate (10mEq/10ml)” NCT03226626 ↗ “500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.” NCT04593238 ↗ “pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg, amoxicillin 1 g for another 5 days” NCT02359435 ↗ “It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle.” NCT06174909 ↗ “The TAP was freshly prepared and proportioned in equal parts by volume (metronidazole, minocycline, and ciprofloxacin=1:1:1) before the scheduled treatment appointment.” NCT04547764 ↗ “Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.” NCT02894268 ↗ “A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), bismuth subcitrate (or bismuth subsalicylate), amoxicillin, and metronidazole.” NCT07260006 ↗ “A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral.” NCT07123792 ↗ “mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.” NCT06821763 ↗ “esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days” NCT01085786 ↗ “Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days” NCT05371249 ↗ “rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid” NCT01566643 ↗ “rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.” NCT01573975 ↗ “Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days” NCT02112214 ↗ “Metronidazole-sensitive strains: Esomeprazole 20 mg, Bismuth Potassium Citrate 220 mg, Amoxicillin 1 g, and Metronidazole 400 mg, twice daily for 14 days.” NCT06760065 ↗ “In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,” NCT02761005 ↗ “a capsule containing 3 agents (Pylera®) containing 125mg metronidazole, 140mg bismuth subcitrate potassium, and 125mg tetracycline was made available.” NCT02045251 ↗ “Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days” NCT02557932 ↗ “Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.” NCT03159754 ↗ “Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation” NCT03763110 ↗ “pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days” NCT01769365 ↗ “with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily” NCT02646332 ↗ “ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.” NCT00881907 ↗ “priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.” NCT02689583 ↗ “Metronidazole tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively” NCT04723069 ↗ “Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days” NCT02395458 ↗ “esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days” NCT04006340 ↗ “Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.” NCT02736682 ↗ “Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid.” NCT03592069 ↗ “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days” NCT03779074 ↗ “pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily” NCT04566211 ↗ “3rd generation cephalosporin (e.g., Cefditoren 200 mg, one tablet every 12 hours) + Metronidazole 500 mg, two tablets every 8 hours.” NCT06517264 ↗ “The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.” NCT01016782 ↗ “Intracanal medicament paste composed of Ciprofloxacin, Metronidazole, and Minocycline. Placed in the root canal for several weeks.” NCT07239739 ↗ “Metronidazole vaginal gel (MVG) 0.75% is a US Food and Drug Administration-approved, 5-day treatment for bacterial vaginosis (BV).” PMID 24983350 ↗ Apr 2015 “Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)” NCT06387147 ↗ “Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients” NCT02148601 ↗ “PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID” NCT01568944 ↗ “Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.” NCT05133193 ↗ “metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days” NCT05332444 ↗ “Metronidazole 500mg two times a day x5 days for Giardia lamblia and 500mg three times a day x7 days for Entamoeba histolytica.” NCT05323396 ↗ “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ “The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.” NCT03565484 ↗ “D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi” NCT01042184 ↗ “The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid.” NCT04238091 ↗ “Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.” NCT07165444 ↗ “Bismuth Quadruple therapy consists of Bismuth subcitrate 120mg QDS, Tetracycline 500mg QDS and Metronidazole 500mg TDS.” NCT07010744 ↗ “pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin” NCT06478940 ↗ “Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days” NCT03730766 ↗ “Regimen 1 (R1): Clarithromycin 500mg BD, plus metronidazole 400mg TDS for 14days and Omeprazole 40mg BD for 6 weeks.” NCT07021729 ↗ “Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days” NCT01938534 ↗ “Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery” NCT03436719 ↗ “Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days” NCT05449028 ↗ “We could not identify any prospective study comparing head to head these two drugs; metronidazole and paromomycin.” NCT06907498 ↗ “Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.” NCT01813162 ↗ “Proton pump inhibitor (eg, omeprazole 20 mg BID), Clarithromycin 500 mg BID, metronidazole 500 mg BID for 14 days” NCT03347513 ↗ “esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.” NCT01306786 ↗ “powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum” NCT02142543 ↗ “Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)” NCT01061437 ↗ “The material is a combination of 3Mix (cefixime, metronidazole, and ciprofloxacin) and a statin (Simvastatin).” NCT06925490 ↗ “two antibiotics (Amoxicillin 30-50mg/kg.d bid, Clarithromycin 15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid)” NCT02635191 ↗ “ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.” NCT00881491 ↗ “I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days” NCT03236961 ↗ “The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.” NCT03863249 ↗ “Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)” NCT01863407 ↗ “Omeprazole 40 mg BID, Metronidazole 400 mg TID, Tetracycline 500 mg QID, Bismuth subsalicylate for 14 days.” NCT07312721 ↗ “ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery” NCT06640439 ↗ “Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.” NCT04209777 ↗ “Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.” NCT07104318 ↗ “will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally.” NCT03969758 ↗ “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.” NCT05829109 ↗ “D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days” NCT03156855 ↗ “D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days” NCT03148366 ↗ “antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days” NCT03043066 ↗ “The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline .” NCT05445362 ↗ “Group 1 (Control): LSTR using Triple Antibiotic Paste (Ciprofloxacin + Metronidazole + Cefixime).” NCT07264842 ↗ “rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days” NCT01265069 ↗ “ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.” NCT04319575 ↗ “lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid” NCT01906879 ↗ “followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days” NCT01537055 ↗ “Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.” NCT03079388 ↗ “control group by SRP with systemic antibiotic administration (spiramycin and metronidazole).” PMID 38395824 ↗ Feb 2024 “tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days” NCT02547038 ↗ “treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole)” NCT03177629 ↗ “Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h” NCT01951768 ↗ “About 50 female patients used Metronidazole tables in the treatment of Bacterial Vaginosis” NCT07247851 ↗ “Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)” NCT04281667 ↗ “Control women with BV will be given oral metronidazole 400mg twice daily for five days” NCT05434104 ↗ “single-dose metronidazole and fluconazole as a means of decreasing vaginal infections” NCT00170430 ↗ “on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)” NCT01967329 ↗ “Giving cephalexin and metronidazole in one group \&cephalexin alone in another group” NCT03736187 ↗ “rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days” NCT01163435 ↗ “Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d” NCT04660123 ↗ “Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.” NCT01559545 ↗ “DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole” NCT05600023 ↗ “broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days” NCT03051698 ↗ “Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.” NCT06443502 ↗ “clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days” NCT04061447 ↗ “D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days” NCT03722433 ↗ “metronidazole (500 mg by intravenous injection every 8 h up to the operation)” PMID 32487213 ↗ Jun 2020 “Metronidazole (MTZ) is considered the drug of choice for the treatment of BV.” NCT02365389 ↗ “3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin” NCT03084601 ↗ “Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively” NCT04977882 ↗ “Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.” NCT04512898 ↗ “Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt)” NCT03533231 ↗ “per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days” NCT03234296 ↗ “a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)” NCT05040334 ↗ “Abnormal vaginal flora will be treated with 2g of oral metronidazole” NCT01287728 ↗ “Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.” NCT05024188 ↗ “Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days” NCT00683865 ↗ “metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole” NCT05977868 ↗ “1:1 metronidazole and ciprofloxacin are mixed with propylene glycol” NCT05079802 ↗ “metronidazole, 400 mg, once a day, vaginal administration, 14 days.” NCT05383521 ↗ “followed by postoperative cefotaxime plus metronidazole for 3 days” NCT07043855 ↗ “Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo” NCT00713947 ↗ “combined with systemic metronidazole (MTZ) and amoxicillin (AMX).” PMID 27013640 ↗ Mar 2016 “Amoxicillin 500 mg, Metronidazole 500 mg, Diclofenac sodium 50 mg” NCT07304882 ↗ “a single dose of metronidazole 500mg 11pm the day before surgery” NCT07429760 ↗ “Metronidazole (Flagyl 500 mg tablets, Sanofi-Aventis, Turkiye)” NCT06818578 ↗ “PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks” NCT02033408 ↗ “Single-dose inj. Metronidazole and Pipperacillin/Tazobactam.” NCT04803422 ↗ “oral antibiotic regimen (e.g. amoxicillin + metronidazole)” NCT04140903 ↗ “the antibiotic (Metronidazole 400mg + Amoxicillin 500mg)” NCT03692819 ↗ “oral metronidazole tablets, 0.4 g three times daily” NCT07512648 ↗ “Metronidazole 500 mg orally twice daily for 5 days” NCT01723059 ↗ “Metronidazole ('Medazol') 500 mg bid for 14 days” NCT03572777 ↗ “metronidazole (500 mg, bid) from day 6 to day 10” NCT00656968 ↗ “with or without adjunctive metronidazole (MTZ).” PMID 28796888 ↗ Sep 2017 “clindamycin, ciprofloxacin and metronidazole” NCT06006663 ↗ “Ciprofloxacin, Metronidazole, & Minocycline” NCT01976065 ↗ “metronidazole 500 mg twice daily for 7 days” NCT03321773 ↗ “Flagyl (metronidazole), 500mg, bid, 7 days” NCT01725906 ↗ “•Doxycyclin, amoxicillin and metronidazole” NCT02345733 ↗ “Doxycyclin, amoxicillin and metronidazole” NCT02217722 ↗ “M is metronidazole (500 mg thrice daily)” NCT06687499 ↗ “metronidazole 400mg qid for last 5 days” NCT01760824 ↗ “Omeprazole+Clarithromycin+Metronidazole” NCT03365609 ↗ “metronidazole 500mg three times a day” NCT04713670 ↗ “Metronidazole 500 mg 2x1, for 14 days” NCT03997279 ↗ “3. Metronidazole: 400mg, 3 times/day” NCT06943794 ↗ “Aztreonam-Avibactam ± Metronidazole” NCT03329092 ↗ “Metronidazole 500mg, PO, BID, 1wk” NCT02759029 ↗ “metronidazole 500mg twice daily” NCT05635942 ↗ “GK567: Metronidazole Gel 0.75%” NCT01541930 ↗ “COL-101, QD plus metronidazole” NCT00495313 ↗ “Metronidazole 400mg tid po” NCT04723472 ↗ “500 mg Metronidazole tab” NCT05677945 ↗ “metronidazole 500mg Tid” NCT01643785 ↗ “Metronidazole (Efloran)” NCT05655338 ↗ “Metronidazole 400mg bd” NCT02092506 ↗ “metronidazole 500mg” NCT06315478 ↗ “metronidazole 500mg” NCT06572761 ↗ “IV metronidazole” NCT01241552 ↗ “Metronidazole” NCT05206500 ↗ “Metronidazole” NCT04751500 ↗ |
| Known as | anaerobic gel | “0.8 % Metronidazole gel (anaerobic gel)” NCT03142607 ↗ |
| Known as | Antibiotics, Metronidazole, Flagyl | “Antibiotics, Metronidazole, Flagyl®” NCT03897244 ↗ |
| Known as | Arilin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02744638 ↗ |
| Known as | Flagyl | “These products are: Metronidazole benzoate (400 mg metronidazole per sachet oral granules)/Terix Labs Ltd, Test product manufactured by ONE PHARMA, Greece and Flagyl™ 400 mg...” NCT02402283 ↗24“Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those...” NCT02942485 ↗ “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗ “Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2).” NCT06798415 ↗ “Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic” NCT02189668 ↗ “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ “Versus Immediate Release Metronidazole (Flagyl) in Patients With Mild to Moderate C. Difficile Associated Diarrhea (CDAD)” NCT01559545 ↗ “Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days.” NCT01568944 ↗ “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt)” NCT03533231 ↗ “Metronidazole (Flagyl 500 mg tablets, Sanofi-Aventis, Turkiye)” NCT06818578 ↗ “3) PD plus a daily single dose of 750 mg Mtz (Flagyl®).” NCT01938183 ↗ “Metronidazole (Flagyl) 400mg qid for last 5 days” NCT01760824 ↗ “Drug: Metronidazole 250 MG Oral Tablet [Flagyl]” NCT04161599 ↗ “D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid” NCT01032655 ↗ “Flagyl (metronidazole), 500mg, bid, 7 days” NCT01725906 ↗ “Metronidazole (Flagyl), 500 mg 3/day” NCT05024188 ↗ |
| Known as | Flagyl (Metronidazole) | “Flagyl (Metronidazole)” NCT01564823 ↗ |
| Known as | Flagyl (Metronidazole), oral suspension. Sanofi-aventis | “Flagyl® (Metronidazole), oral suspension. Sanofi-aventis” NCT01314976 ↗ |
| Known as | Flagyl ER | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | flasinyl | “metronidazole, flasinyl® 500mg tid 5 days (D6-D10)” NCT02373280 ↗ |
| Known as | GK567 | “GK567: Metronidazole Gel 0.75%” NCT01541930 ↗ |
| Known as | GK567: Metronidazole Gel 0.75% | “GK567: Metronidazole Gel 0.75%” NCT01541930 ↗ |
| Known as | Likmez | “Likmez® (metronidazole) Oral Suspension” NCT07146217 ↗ |
| Known as | Medazol | “Metronidazole ('Medazol') 500 mg bid for 14 days” NCT03572777 ↗ |
| Known as | MET | “Herein, we aim to evaluate the effectiveness of oral Chinese-origin Lactobacillus with adjuvant metronidazole (MET) on treating Chinese BV patients.” PMID 37575226 ↗ Jul 20234“Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species.” NCT00066066 ↗ “Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI” NCT04721704 ↗ “amoxicillin + metronidazole (AMX + MET) versus clarithromycin (CLM)” PMID 31257591 ↗ Jul 2019 “ceftriaxone-metronidazole (CTX/MET)” PMID 22439781 ↗ Mar 2012 |
| Known as | metraonidazoel | “amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week” NCT06065267 ↗ |
| Known as | METRO | “two metronidazole (METRO) tablets and one doxycycline hyclate (DOXY) simulant at a time, twice daily for 14 days” PMID 38584600 ↗ Mar 20241“Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.” NCT00002682 ↗ |
| Known as | MetroGel | “Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days” NCT02766023 ↗4“MetroGel® (metronidazole gel), 1.0% 1x/day” NCT00249782 ↗ “Metronidazole Topical Gel 1% (Metrogel)” NCT01513863 ↗ “Metronidazole (Metrogel)” NCT00855595 ↗ |
| Known as | Metrogyl | “Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.” NCT00360607 ↗ |
| Known as | Metronidazol | “Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.” NCT01572558 ↗6“Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.” NCT06107569 ↗ “Metronidazol” NCT02099240 ↗ |
| Known as | Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany) | “Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany)” NCT01524081 ↗ |
| Known as | Metronidazole (Efloran) | “Metronidazole (Efloran)” NCT05655338 ↗ |
| Known as | Metronidazole Hydrochloride | “Drug: Metronidazole Hydrochloride” NCT00002682 ↗ |
| Known as | Metronidazole Vaginal Gel 0.75% | “Metronidazole Vaginal Gel 0.75% is an FDA-approved drug” NCT03091777 ↗ |
| Known as | Metronidazole-DRF1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01559545 ↗ |
| Known as | Metronidazole-DRF2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01559545 ↗ |
| Known as | Metronidazole-Flagyl | “Metronidazole-Flagyl®” NCT02033408 ↗1“Metronidazole: Flagyl” NCT01219764 ↗ |
| Known as | MNZ | “Metronidazole (MNZ)-based re-eradication therapy, such as triple PPI/AMPC/MNZ therapy, also achieved high eradication rates and has been recommended as the second line therapy in Japan.” NCT00197418 ↗1“Although metronidazole (MNZ) has been used worldwide for more than 4 decades” PMID 25442806 ↗ Nov 2014 |
| Known as | MTZ | “The benefits of amoxicillin (AMX) plus metronidazole (MTZ) adjunctive to scaling and root planing (SRP) require further investigation, particularly in individuals with a high...” NCT05934227 ↗10“They will be randomized into one of two arms; metronidazole (MTZ) 2 g single dose (CDC recommended treatment regimen) or MTZ 500 mg twice daily x 7-day dose (CDC alternative...” NCT01832480 ↗ “The authors compared the effect of metronidazole (Mtz) on full-mouth periodontal debridement (PD= 1 hour of ultrasonic calculus/plaque removal) in smokers with CP.” NCT01938183 ↗ “Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy” NCT04189744 ↗ “The metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative)” PMID 21423852 ↗ Dec 2010 “Children in MTZ-based triple regimen received metronidazole, PPI, and clarithromycin for 14 days.” NCT07086937 ↗ “The porous metronidazole (MTZ) loaded matrix was fabricated by the freeze-drying technique.” NCT03791099 ↗ “Metronidazole (MTZ) is considered the drug of choice for the treatment of BV.” NCT02365389 ↗ “AIM: To evaluate the effects of the adjunctive use of metronidazole (MTZ) or” PMID 23016867 ↗ Sep 2012 “combined with systemic metronidazole (MTZ) and amoxicillin (AMX).” PMID 27013640 ↗ Mar 2016 “with or without adjunctive metronidazole (MTZ).” PMID 28796888 ↗ Sep 2017 |
| Known as | Noritate | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | NSC-50364 | “Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.” NCT00002682 ↗ |
| Known as | Rosadan | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | Tricho gel | “Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days” NCT02365389 ↗ |
| Known as | Vandazole | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Known as | Vitazol | “Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)” NCT01731236 ↗ |
| Modality | Small molecule | “Metronidazole is a nitroimidazole.” NCT02766023 ↗ |
| Route | Oral | “oral metronidazole tid on days 4-10” NCT00003151 ↗ |